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Abstract
Diabetic nephropathy (DN) is a primary cause of end-stage renal disease and is becoming more prevalent
because of the global rise in type 2 diabetes. A model of DN, the db/db uninephrectomized (db/db-uni)
mouse, is characterized by obesity, as well as compromised renal function. This model also manifests
defects in mineral metabolism common in DN, including hyperphosphatemia, which leads to severe
endocrine disease. The FGF23 coreceptor, α-Klotho, circulates as a soluble, cleaved form (cKL) and may
directly influence phosphate handling. Our study sought to test the effects of cKL on mineral metabolism in
db/db-uni mice. Mice were placed into either mild or moderate disease groups on the basis of the albumin-
to-creatinine ratio (ACR). Body weights of db/db-uni mice were significantly greater across the study
compared with lean controls regardless of disease severity. Adeno-associated cKL administration was
associated with increased serum Klotho, intact, bioactive FGF23 (iFGF23), and COOH-terminal fragments
of FGF23 (P < 0.05). Blood urea nitrogen was improved after cKL administration, and cKL corrected
hyperphosphatemia in the high- and low-ACR db/db-uni groups. Interestingly, 2 wk after cKL delivery,
blood glucose levels were significantly reduced in db/db-uni mice with high ACR (P < 0.05). Interestingly,
several genes associated with stabilizing active iFGF23 were also increased in the osteoblastic UMR-106
cell line with cKL treatment. In summary, delivery of cKL to a model of DN normalized blood phosphate
levels regardless of disease severity, supporting the concept that targeting cKL-affected pathways could
provide future therapeutic avenues in DN.
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NEW & NOTEWORTHY In this work, systemic and continuous delivery of the “soluble” or “cleaved”
form of the FGF23 coreceptor α-Klotho (cKL) via adeno-associated virus to a rodent model of diabetic
nephropathy (DN), the db/db uninephrectomized mouse, normalized blood phosphate levels regardless of
disease severity. This work supports the concept that targeting cKL-affected pathways could provide future
therapeutic avenues for the severe mineral metabolism defects associated with DN.
Keywords: cKL, diabetes, FGF23, Klotho, phosphate
INTRODUCTION
Diabetes is currently the greatest risk factor for developing chronic kidney disease (CKD), affecting >40%
of patients with diabetes (60). The db/db mouse line is a genetic obese hyperinsulinemic model of diabetes
that develops renal abnormalities similar to patients with type 2 diabetes (67). The db gene encodes a G > T
point mutation in the leptin receptor that alters hypothalamic responses, causing obesity, hyperlipidemia,
hyperinsulinemia, insulin resistance, and diabetes (9, 43). Performing uninephrectomies on db/db mice
accelerates the progression of diabetic nephropathy (DN) by increasing the strain on the remaining diabetic
kidney (29), with a 70% increase in mesangial thickening (6). Nephrectomies at earlier ages of db/db mice
(6–10 wk) result in profound renal defects by 20–24 wk of age. Typically, a db/db mouse
uninephrectomized at 6 wk of age will exhibit an increase in albumin-to-creatinine ratio (ACR; 56, 57) by 8
wk of age and a decrease in glomerular filtration rate by 24 wk of age (21, 55). Testing therapeutic
interventions in this model of accelerated DN has been useful, particularly in the area of pharmacological
inhibitor development for treating renal injury (29, 55, 71).
DN is also associated with development of chronic kidney disease-mineral bone disorder (CKD-MBD; 2,
22). CKD-MBD is clinically characterized in stages of declining kidney function with severe endocrine
bone disease, as well as elevated serum parathyroid hormone and bioactive “intact” fibroblast growth factor
23 (iFGF23; 51, 54). CKD-MBD disrupts the normal bone-kidney endocrine axis responsible for regulating
mineral metabolism, and hyperphosphatemia develops in late-stage disease (48, 51). In healthy individuals
the hormone FGF23, primarily produced by bone, and α-Klotho (α-KL) aid in maintaining normal
phosphate and vitamin D homeostasis (40, 41, 45, 72). It is thought that, in part, the hyperphosphatemia
due to loss of renal function in CKD leads to increased production of FGF23 (31, 42). Although FGF23
compensates temporarily to maintain normal serum phosphate, with loss of renal mass a decrease in α-KL
expression is observed (39). This setting likely leads to “FGF23 resistance” and marked rises in serum
phosphate (52).
Two main forms of α-KL protein exist: a full-length transmembrane isoform (mKL; 135 kDa), primarily
found in the kidney and parathyroid gland, and a circulating soluble form (cKL; 110 kDa) that can be
detected in blood, urine, and cerebrospinal fluid (40). FGF23 initiates signaling through an assembly of
mKL coreceptor complexed with FGF receptors (FGFRs), leading to activation of the MAPK cascade (24,
41, 44, 58, 72). The cKL polypeptide, composed of KL1 and KL2 extracellular domains, is generated from
cleavage of mKL via activity of the disintegrin and metalloproteinase domain-containing protein-10/17
(ADAM10/17) and β-secretase 1 (BACE) cell surface proteases (49). Prior studies have shown the
capability of cKL, in coordination with FGF23, to reduce serum phosphate in normal rodents and the
hyperphosphatemic KL-null mouse (30, 68).
Circulating iFGF23 concentrations are regulated by intracellular furin-mediated protease cleavage of
FGF23 (70, 73), with polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3)-mediated
O-glycosylation activity protecting iFGF23 (4, 37) and extracellular serine/threonine protein kinase
FAM20C (FAM20C) kinase activity destabilizing iFGF23 (70). These changes can be detected in blood by
measuring COOH-terminal fragments of FGF23, or cFGF23, by ELISA (35, 74). The posttranslational
regulation of mature FGF23 is critical for regulating serum iFGF23 concentrations, as metabolic challenges
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Animal studies.
Uninephrectomy.
Recombinant cKL and FGF23 and AAV-cKL production.
Histology.
such as anemia and hypoxia result in markedly elevated FGF23 mRNA but normal iFGF23 elevated
cFGF23 due to proteolysis, to maintain proper phosphate handling in rodents (10, 16) and in humans (7, 32,
61, 63). Importantly, during CKD and with other genetic changes, including inactivating mutations in
phosphate-regulating gene with homology to peptidases on the X chromosome (PHEX) and dentin matrix
protein-1 (DMP1), resulting in X-linked hypophosphatemia and autosomal recessive hypophosphatemic
rickets type 1, respectively, causes “inappropriate” overproduction of iFGF23 (3, 12, 13, 33, 35, 47, 62,
75). The mechanisms responsible for maintaining high iFGF23 are not clear. Herein, we sought to test
stable delivery of cKL in a model of DN with mild or moderate degrees of kidney disease and effects on
manifestations of CKD-MBD. With sustained cKL delivery to db/db-uni mice, blood urea nitrogen (BUN)
was partially corrected in moderately severe CKD, and hyperphosphatemia was reduced regardless of
disease severity. Additionally, intact, bioactive iFGF23 was elevated with cKL delivery in parallel with
changes in genes associated with a shift in the balance of inactive cFGF23 to iFGF23, supporting the idea
that cKL may alter FGF23 processing. Collectively, these findings support the concept that treatment with
cKL promotes the expression of genes associated with stabilizing active iFGF23 and targeting Klotho-
responsive pathways could potentially provide therapeutic benefit across disease stages in DN.
METHODS
Animal studies were performed according to a protocol approved by the Institutional
Animal Care and Use Committee for Indiana University and the internal review board at Eli Lilly and
Company and comply with the National Institutes of Health guidelines for the use of animals. Adeno-
associated virus 2/8 expressing cKL (AAV-cKL) or AAV-LacZ was delivered to db/db uninephrectomized
(db/db-uni) mice via retro-orbital injection at 1 × 10  genomic copies per mouse as previously described
(68). Used as “lean,” normal age-matched controls, db/dm mice were not treated. Body weights and interim
bleeds were taken at indicated times, and all mice were euthanized after 6 wk of treatment using CO
inhalation and then cervical dislocation.
Uninephrectomy surgery was performed at Harlan Laboratories (Indianapolis, IN) at 4
wk of age, and mice were shipped 1 wk postsurgery. The ACR was measured on the Hitachi analyzer
(Roche Diagnostics). The creatinine was measured using Roche’s Creatinine Plus reagent, and the albumin
was measured using Eli Lilly’s modified assay. ACR was calculated as albumin/creatinine × 100 and
reported as a percentage. Prior to the start of the study, all mice were rank ordered by their urine ACR from
low to high. The lowest 24 were designated as the low-ACR group, whereas the highest 32 animals were
used in the high-ACR group. The lowest 24 ACR values were used for groups “low ACR/LacZ” (received
AAV-LacZ) and “low ACR/cKL” (received AAV-cKL), whereas the 32 animals with highest ACR were
used for groups “high ACR/LacZ” and “high ACR/cKL.”
As previously reported (30, 68), the cDNA
encoding residues 35–983 of the extracellular domain of mouse α-KL (cKL) with a CD33 NH -terminal
signal sequence, or β-galactosidase gene cassette (LacZ) as a vector control, was packaged into a
recombinant hybrid AAV vector (RegenX Biosciences). Both AAV-cKL and AAV-LacZ localize to the
liver, as previously reported (30). Recombinant cKL (mouse) and FGF23 (human) were purchased from
R&D Systems.
Kidneys from the db/dm (lean) or db/db-uni mice were removed at euthanasia and fixed for at
least 24 h in 10% neutral buffered formalin. Tissues were trimmed, routinely processed, embedded in
paraffin and sectioned, and then stained with hematoxylin-eosin (H&E), Masson’s trichrome (MTS), or
periodic acid-Schiff (PAS) stains. Histopathological evaluation of these slides was conducted by an
American College of Veterinary Pathologists-certified pathologist using an internally established grading
system.
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Serum and urine biochemistries.
Cell culture and in vitro functional assays.
RNA isolation and quantitative PCR.
Statistical analyses.
cKL delivery partially corrects defective mineral metabolism in db/db-uni mice.
Whole blood was collected from tail sticks at times stated. Standard
calcium, inorganic phosphorus, and BUN reagent kits were utilized for serum measurements in a Hitachi
analyzer (Roche Diagnostics). Serum cKL was measured as previously described (68); serum FGF23 was
tested using “Intact” FGF23 ELISA (Quidel) and “C-Term” FGF23 ELISA (Quidel). Blood glucose
measurements in the lean controls and db/db-uni mice were performed using a Roche Aviva Accu-Chek
glucometer. Urine ACR was obtained through spot urine collections over a 2–3-h period and analyzed as
previously described (27).
UMR-106 cells (American Type Culture Collection) were
cultured in DMEM/F-12 (Invitrogen) supplemented with 10% fetal bovine serum (Hyclone), 1 mM sodium
pyruvate, 25 mM අ-glutamine, and 25 mM penicillin-streptomycin (Sigma-Aldrich) at 37°C and 5% CO .
Cells were plated at 1.0 × 10  cells per well in 12-well plates and treated for 18 h with doses of cKL (30
nM) and FGF23 (115 nM) before RNA extraction.
RNA from UMR-106 cells was isolated from cellular lysates using
the RNeasy kit (Qiagen). RNA samples were tested by quantitative PCR with primers specific for rat
DMP1, FAM20C, GALNT3, FGFR1, FGFR2, FGFR3, FGFR4, and internal control β-actin (ACTB) as
previously described (16). The TaqMan One-Step RT-PCR kit (Life Technologies) was used to perform
quantitative PCR, and data were collected using the 7500 Real Time PCR system and software (Life
Technologies) and then analyzed using the comparative threshold cycle (2 ) method (46).
Significance between groups was assessed using ANOVA analysis with a Tukey
honestly significant difference post hoc test. Significance for all tests was set at P < 0.05, and data are
presented as means ± SE.
RESULTS
Extensive
immunohistochemistry was performed on db/db-uni mice to examine the similarities of this model to the
clinical presentation of patients with DN. Performing uninephrectomy surgery on db/db mice at 4 wk of age
led to marked renal pathogenesis (Fig. 1, B, D, and F) compared with lean controls (Fig. 1, A, C, and E). In
this regard, H&E-stained sections of db/db-uni mice revealed a dilated renal pelvis (RP) with focally
extensive inflammatory infiltrate (black arrows) that extended into the transitional epithelial lining (Fig. 1B
). Similar to other studies, we found that MTS-stained sections depicted increased fibroplasia in glomeruli
(increased blue matrix) with a relative paucity of open capillary loops (Fig. 1D; yellow arrows) compared
with the normal glomeruli in lean controls (Fig. 1C, stars; 14, 29). Minimal interstitial fibrosis between the
tubules is also highlighted in blue (Fig. 1D). PAS-stained sections demonstrated normal mesangial matrix
and open capillary loops (Fig. 1E, stars). Significantly increased mesangial matrix deposition was present
that frequently obliterated the normal capillary loops (Fig. 1F, yellow arrows) and cellularity in the
glomeruli (Fig. 1E compared with Fig. 1F). Open and closed capillary loops can be a function of tissue
sectioning. However, in the presence of a pathological process that involves increased mesangial matrix
and other changes in the glomerular architecture along with the uniformity of closed capillary loops
observed, we attributed this change to the pathological process itself and not effects of the tissue-sectioning
process. Glomeruli in db/db-uni LacZ mice were also slightly larger than in the lean mice, potentially
because of functional hypertrophy subsequent to uninephrectomy (Fig. 1F). These collective phenotypes
are similar to those of patients with DN (19), thus providing a suitable model to explore cKL function in
renal disease.
To examine the effects of cKL on DN phenotypes, the db/db-uni mice were treated with AAV-cKL or AAV-
LacZ for 6 wk after the mice were segregated into mild-stage (low ACR) or moderate-stage (high ACR)
CKD groups. For baseline references, lean control mice were used without AAV-cKL treatment. The lean
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Changes in genes associated with FGF23 processing.
mice were significantly lower in weight than all db/db-uni mice, regardless of ACR or treatment (Fig. 1G;
P < 0.05). Heart weight-to-body weight ratios of the db/db-uni mouse groups were reduced compared with
lean controls because of the elevated body weights of the db/db-uni mice but were not different across
db/db-uni groups (Fig. 1H; P < 0.05). Creatinine was elevated in the low-ACR/LacZ, high-ACR/LacZ, and
high-ACR/cKL groups (Fig. 2A; P < 0.05), and BUN was significantly higher in high ACR/LacZ compared
with lean mice (Fig. 2B; P < 0.01 vs. lean). AAV-cKL treatment was associated with partially normalized
BUN in the high-ACR group (Fig. 2B; P < 0.01 vs. high ACR/LacZ). Blood glucose of lean control mice
was significantly lower than that of all db/db-uni mice (Fig. 2C; P < 0.01). Two weeks of AAV-cKL
treatment led to significantly lower blood glucose values in the high-ACR/cKL group (Fig. 2C; P < 0.05).
Elevated FGF23 has been shown to be directly associated with cardiac hypertrophy (17, 26, 50). Although
we observed significantly increased FGF23 with cKL delivery, we detected no changes in myocardial
degeneration or fibrosis (not shown).
The db/db-uni mice in both the low-ACR/LacZ and high-ACR/LacZ groups were hyperphosphatemic
compared with lean controls at euthanasia (Fig. 3A; P < 0.01). After AAV-cKL administration, serum
phosphate was significantly reduced compared with AAV-LacZ controls in both the low- and high-ACR
groups (Fig. 3A; P < 0.01). In addition, AAV-cKL treatment in high-ACR db/db-uni mice significantly
reduced serum phosphate compared with lean mice (Fig. 3A; P < 0.01). With AAV-cKL delivery, serum
Klotho levels in db/db-uni mice were significantly increased, in agreement with previous studies (Fig. 3B;
P < 0.01; 30, 68). AAV-cKL treatment was also associated with reduced serum calcium in the low- and
high-ACR groups (Fig. 3C; P < 0.05 vs. respective ACR/LacZ). The db/db-uni mice, regardless of ACR
levels, had elevated serum alkaline phosphatase (Fig. 3D; P < 0.05 vs. lean). Treatment with AAV-cKL
further elevated serum alkaline phosphatase in low- and high-ACR groups (Fig. 3D; P < 0.05 vs. respective
ACR/LacZ). Thus, cKL delivery was associated with a reduction in serum phosphate, and this effect
occurred under both mild and moderately severe disease conditions.
Interestingly, cKL treatment strongly induced
iFGF23 (and, predictably, cFGF23 since both circulating species are measured by the cFGF23 ELISA) in
the low- and high-ACR/cKL groups at 4 and 6 wk post-AAV-cKL injection (Fig. 4, A and B; P < 0.01).
Therefore, cKL may influence the normal cellular regulation of iFGF23 production through influencing
processing of the mature hormone. To test genes potentially associated with controlling circulating iFGF23-
to-cFGF23 ratios, the UMR-106 osteoblastic cell line was treated overnight with cKL either alone (30 nM)
or in combination with FGF23 (115 nM). Expression of the pro-iFGF23 enzyme GALNT3 mRNA
increased 2.2-fold, whereas the expression of mRNAs encoding the iFGF23-destabilizing genes DMP1 and
FAM20C increased 10.5- and 5.5-fold respectively, potentially as a compensatory response following
cKL+FGF23 delivery (Fig. 5A; P < 0.01). cKL treatment alone did not induce changes in GALNT3,
DMP1, or FAM20C. FGFR expression was affected by cKL and FGF23 treatment, as FGFR1, FGFR2, and
FGFR3, but not FGFR4, were significantly reduced after overnight treatment (Fig. 5B; P < 0.05).
In sum, we found that stable delivery of cKL to a model of DN improved hyperphosphatemia in both mild
and moderate stages of kidney disease. Treatment with cKL led to a shift in proportional increases of intact,
bioactive iFGF23 and cFGF23. Our findings support the concept that targeting Klotho-responsive pathways
could be therapeutically beneficial across various stages of DN.
DISCUSSION
DN is one of the primary causes of end-stage renal disease and is becoming increasingly prevalent because
of the increase in type 2 diabetes. To begin to understand the role of cKL and FGF23 in DN, we used a DN
mouse model derived through uninephrectomy of the db/db diabetic mouse. We segregated db/db-uni mice
into mild “low ACR” and moderate “high ACR” kidney disease, allowing analysis of the effects of cKL
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across a CKD severity spectrum. Glomerular filtration rate was not directly assessed but could be
considered in future studies. The db/db-uni model has been used to examine pharmacological inhibitors in
the prevention of diabetic renal injury (29, 55, 71). In this regard, short-term administration of plasminogen
activator inhibitor-1 (PAI-1) slowed the progression of glomerulosclerosis but had no effect on blood
glucose or creatinine (29). Similarly, glomerulosclerosis was reduced by frequent and prolonged
administration of an antagonist of the monocyte chemoattractant C-C chemokine ligand 2 (CCL2) but did
not lower db/db-uni blood glucose (55). The insulin sensitizer, rosiglitazone, reduced glomerulosclerosis
and lowered serum creatinine and albuminuria (71). Recently, a combination treatment of a PAI-1
neutralizing antibody and enalapril, a blood pressure-reducing agent, has shown some promise in slowing
DN in db/db-uni mice by reducing albuminuria and markers of renal fibrosis (25). Since elevated blood
phosphate is associated with more rapid CKD progression in patients (34, 64), combination therapies with
the agents above and AAV-cKL could potentially lessen overall disease burden.
In our analysis, the db/db-uni mice were apportioned into low- and high-ACR groups to test whether AAV-
cKL could improve outcomes across several CKD stages. Prior DN animal studies grouped mice by
reduction in kidney function from administering low or high doses of streptozotocin (STZ; 36, 53). Higher
doses of STZ resulted in increased albuminuria and worse glomerular filtration rate compared with the
lower STZ dose. Interesting, AAV-cKL was associated with reducing serum phosphate regardless of kidney
function status, but whether this activity was solely due to the increase in FGF23 or through direct actions
of cKL on the kidney phosphate transporter activity (11, 28, 65, 69) remains to be determined. In future
experiments, examination of fractional excretion of phosphate could gauge kidney tubular function and
confirm mechanistically that the reduced serum phosphate occurred through increased phosphate excretion.
Therefore, our results suggest that targeting cKL-mediated pathways in both mild and moderate CKD
disease states would provide benefit in ameliorating defective mineral metabolism.
It is well established that patients with CKD have increased cardiovascular morbidity, particularly those in
the advanced stages of renal disease (5, 20, 23). We found no definitive evidence of LVH in db/db-uni mice
compared with lean control mice in both mild and moderate disease groups. Previous work in db/db mice
reported a reduction in myocardial degeneration via changes in the expression patterns of cardiac
remodeling genes after administration of phlorizin, a competitive inhibitor of glucose storage (8).
Importantly, FGF23 has been associated with adverse patient outcomes for cardiac disease (38, 59, 66).
Although cKL delivery increased FGF23, we found no increase in heart weight-to-body weight ratios,
suggesting potential protective effects of cKL in the db/db-uni mice. Whether cKL protects heart function
through inhibiting off-target FGF23 activity remains unknown. We did not detect cardiac calcifications in
the db/db-uni model at baseline; however, when db/db-uni mice were fed a high-phosphate diet, renal
calcification and cardiac dysfunction were reported to occur (14). We have shown AAV-cKL delivery to be
capable of reducing hyperphosphatemia-induced calcification (30); thus, future work could expand cKL’s
utility by examining AAV-cKL administration in db/db-uni mice fed a high-phosphate diet.
Six weeks of cKL administration led to an increase in bioactive iFGF23 and a corresponding decrease in
serum phosphate, similar to our findings in prior work (30, 68). Interestingly, cKL treatment increased
iFGF23 and cFGF23, resulting in a nearly 1:1 iFGF23-to-cFGF23 ratio. This result contrasts with previous
findings of FGF23 proteolytic processing during other metabolic challenges, including states of iron
deficiency anemia (16). In this regard, wild-type mice responded to anemia by cleaving mature FGF23 to
maintain normal blood iFGF23, leading to marked elevation in cFGF23 fragments. Additionally, patients
with hyperphosphatemic familial tumoral calcinosis due to FGF23 or GALNT3 mutations have increased
proteolysis of iFGF23, resulting in low serum concentrations of bioactive hormone. The molecular nature
of the increased iFGF23-to-cFGF23 ratio in response to cKL administration remains to be determined, but
this could be a potential avenue for increasing blood concentrations of iFGF23 when deficient.
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Our in vitro studies support the idea that a change in FGF23 processing occurs after treatment with
cKL+FGF23, as GALNT3 mRNA increased, which would favor production of iFGF23. We also found that
the mRNAs from genes that are associated with FGF23 cleavage, including DMP1 and FAM20C, were
increased. This result may suggest a potential compensatory response mechanism to balance iFGF23-to-
cFGF23 ratios. The gene DMP1 has been previously determined to be mutated in patients with autosomal
recessive hypophosphatemic rickets, resulting in marked upregulation of iFGF23 (15). In agreement with
this phenotype, FGF23 mRNA and iFGF23 are significantly increased in osteoblast/osteocyte-specific
DMP1-conditional and global DMP1 knockout mice (18). Importantly, the genetic loss of DMP1 and the
overexpression of cKL are similar in that they result in overriding the typically suppressive effects of
hypophosphatemia on suppressing FGF23 production (1). Certainly, the exact mechanisms guiding
iFGF23-to-cFGF23 ratios due to dynamic changes in mRNA expression, protein production, and activity of
intracellular protein-processing systems in osteoblasts/osteocytes remain to be fully resolved.
In sum, our results demonstrate that providing cKL in DN can reduce serum phosphate during mild and
moderate disease states, as well as potentially ameliorate other biochemical outcomes, supporting the
concept of targeting cKL-mediated pathways for control of mineral metabolism.
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Fig. 1.
Various stages of diabetic nephropathy are exhibited by db/db uninephrectomized (db/db-uni) mice, and treatment with the
circulating soluble form of α-Klotho (cKL) reduces hyperphosphatemia: representative differences in histopathological
changes in kidneys from lean mice (A, C, and E) and db/db-uni LacZ mice (B, D, and F). A: hematoxylin-eosin (H&E)-
stained section with normal renal pelvis (RP) and absence of inflammation. B: H&E-stained section showing a dilated
renal pelvis with focally extensive inflammatory infiltrate (black arrows) that extends into the transitional epithelial lining.
C: Masson’s trichrome (MTS)-stained section showing normal glomeruli with open capillary loops and normal mesangial
matrix (stars). D: MTS-stained section depicting increased fibroplasia in glomeruli (increased blue matrix) with relative
paucity of open capillary loops (yellow arrows). Inset shows a sclerotic glomerulus that has lost the normal glomerular
architecture. Minimal interstitial fibrosis between the tubules is also highlighted in blue. E: periodic acid-Schiff (PAS)-
stained section demonstrating normal mesangial matrix and open capillary loops (stars). F: significantly increased
mesangial matrix deposition highlighted by PAS staining that frequently obliterates the normal capillary loops and
cellularity in the glomeruli (yellow arrows). Glomeruli in db/db-uni LacZ mice are slightly larger than those in the lean
mice because of functional hypertrophy subsequent to uninephrectomy. G: lean control (db/dm) mice were significantly
lighter than all db/db-uni mice, regardless of albumin-to-creatinine ratio (ACR) or treatment group (*P < 0.05). H: all
db/db-uni mice, regardless of ACR or treatment group, had a lower heart weight-to-body weight (BW) ratio compared
with lean controls (*P < 0.05).
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Fig. 2.
Administering adeno-associated virus 2/8 expressing the circulating soluble form of α-Klotho (AAV-cKL) to db/db
uninephrectomized (db/db-uni) mice moderately improves kidney function and blood glucose. A: creatinine was elevated
in low-albumin-to-creatinine ratio (ACR)/LacZ, high-ACR/LacZ, and high-ACR/cKL groups compared with lean controls
(*P < 0.05). B: blood urea nitrogen (BUN) was significantly higher in high ACR/LacZ (**P < 0.01 vs. lean). AAV-cKL
treatment reduced BUN after 6 wk (#P < 0.01 vs. high ACR/LacZ). C: blood glucose of lean control mice was
significantly lower than that of all db/db-uni mice (*P < 0.01). Two weeks of AAV-cKL treatment significantly reduced
blood glucose values in the high-ACR/cKL group (#P < 0.05).
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Fig. 3.
Endocrine effects of adeno-associated virus 2/8 expressing the circulating soluble form of α-Klotho (AAV-cKL) in lean
and db/db uninephrectomized (db/db-uni) mice. A: db/db-uni mice in both the low- and high-albumin-to-creatinine ratio
(ACR) groups were hyperphosphatemic (**P < 0.01 vs. lean). Serum phosphate was significantly reduced in db/db-uni
mice in both the low- and high-ACR groups 6 wk after AAV-cKL injection (#P < 0.01 vs. respective LacZ). AAV-cKL
treatment in high-ACR db/db-uni mice significantly reduced serum phosphate compared with lean mice (**P < 0.01). B:
serum Klotho levels in db/db-uni mice were significantly increased with AAV-cKL treatment 6 wk postinjection (**P <
0.01 vs. lean and respective LacZ). C: serum calcium was elevated in db/db-uni mice in both the low- and high-ACR
groups treated with AAV-LacZ (*P < 0.05 and **P < 0.01 vs. lean). AAV-cKL treatment reduced serum calcium in both
the low- and high-ACR groups (#P < 0.05 vs. respective ACR/LacZ). D: db/db-uni mice, regardless of ACR group, have
elevated serum alkaline phosphatase (Alk Phos; *P < 0.05 and **P < 0.01 vs. lean). Treatment with AAV-cKL further
elevated serum alkaline phosphatase in low- and high-ACR groups (#P < 0.05 vs. respective ACR/LacZ).
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Fig. 4.
Changes in FGF23 processing with treatment with the circulating soluble form of α-Klotho (cKL) and downstream targets.
A: intact FGF23 was significantly elevated in low- and high-albumin-to-creatinine ratio (ACR) groups of db/db
uninephrectomized (db/db-uni) mice treated with adeno-associated virus 2/8 expressing cKL (AAV-cKL) at 4 and 6 wk
postinjection (**P < 0.01). Six- and eight-week control values for intact FGF23 were as follows: db/dm: 133.8 ± 23.7 and
153.7 ± 8.2; low-ACR LacZ: 156.4 ± 25.2 and 233.5 ± 48.0; high-ACR LacZ: 209.0 ± 50.8 and 361.5 ± 102.5,
respectively. B: COOH-terminal (C-term) fragments of FGF23 were significantly elevated in low- and high-ACR groups
of db/db-uni mice treated with AAV-cKL at 4 and 6 wk postinjection (**P < 0.01). Control values for C-term FGF23 were
as follows: db/dm: 1.1 ± 0.6; low-ACR LacZ: 29.9 ± 16.1; high-ACR LacZ: 415.5 ± 388.0.
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Fig. 5.
Changes in downstream targets of FGF23 signaling and FGF receptor (FGFR) expression with treatment with the
circulating soluble form of α-Klotho (cKL). A: cKL and FGF23 combination treatment (FGF23 + KL) increased
polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3; *P < 0.05), dentin matrix protein-1 (DMP1; **P < 0.01), and
extracellular serine/threonine protein kinase FAM20C (FAM20C; *P < 0.05) mRNA expression. cKL treatment alone
(KL) had no effect on mRNA expression. B: FGFR1, FGFR2, and FGFR3 mRNA expression was significantly reduced by
combination treatment of cKL and FGF23 (*P < 0.05). FGFR4 mRNA expression was not statistically different from
control following combination treatment.
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